Why Vitrolife stock moves
Vitrolife held steady, moving less than the wider market.
Written after the close on ·
Why today
15,984 news analyzed todayVitrolife held steady, moving less than the wider market.
Over the last five trading days, Vitrolife rose clearly while the OMX Stockholm 30 was roughly flat.
The move was ordinary for Vitrolife, and no company news explains the last session.
Earlier, Vitrolife named Elin Frostehav as its new CEO, succeeding Bronwyn Brophy O'Connor, and appointed its nomination committee for the 2027 AGM.
Next, Vitrolife reports earnings on Thursday 28 January 2027.
Today's move of −0.25% was 0.3 times a normal day's 0.9%. OMX Stockholm 30 moved −1.01% on the same day.
Vitrolife −0.25%OMX Stockholm 30 −1.01%A little stronger than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Vitrolife.
Vitrolife earned more than expected in 4 out of 8 reports.
Not in the chart because no estimate and result are available: 1 of the 9 reports in this period, the latest on October 23, 2025.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 5 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 120.10 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 1.03 SEK (January 28). For the current fiscal year, expected earnings per share changed from 4.43 SEK three months ago to 4.56 SEK now. 2026 estimate: 4.56 SEK. 2027 estimate: 5.52 SEK. One analyst made the estimate for the quarter. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. February 6: Buy about 270 thousand SEK. February 6: Buy about 578 thousand SEK. February 4: Buy about 197 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 2 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −36% and earnings per share went from 3.79 SEK to -37.01 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 2 out of 3 years.Market cap (Now): 15.9 bn SEKRevenue 2025: 3.4 bn SEK
What the key figures say about Vitrolife
The figures connect what Vitrolife earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -37.01 SEK–3.79 SEK. Peers: Embla Medical 1.42 DKK, Nolato 2.50 SEK, Elekta -0.95 SEK. 2026 estimate: 4.56 SEK (3.65 SEK–5.62 SEK). 2027 estimate: 5.52 SEK (4.48 SEK–6.83 SEK).
What the company sold during the year.
2022–2025: 3.2 bn SEK–3.6 bn SEK. Peers: Embla Medical $997M, Nolato 9.6 bn SEK, Elekta 16.6 bn SEK. 2026 estimate: 3.5 bn SEK (3.5 bn SEK–3.5 bn SEK). 2027 estimate: 3.8 bn SEK (3.8 bn SEK–3.9 bn SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: 16.7%–21.9%. Peers: Embla Medical 13.6%, Nolato 10.0%, Elekta 1.7%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −63.5%–3.8%. Peers: Embla Medical 10.4%, Nolato 11.8%, Elekta −4.3%.
What investors pay for each unit the company sells.
2022–2025: 5.39–8.07. Peers: Nolato 1.43, Elekta 1.40. 2026 estimate: 4.54. 2027 estimate: 4.17.
Money paid to shareholders per share, summed by calendar year.
2017–2025: 0.00 SEK–1.10 SEK.
The ordinary yearly dividend as a percentage of the share price.
2022–2025: 0.4%–0.8%. Peers: Embla Medical 0.0%, Nolato 3.3%, Elekta 4.0%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: 0.79–1.69. Peers: Embla Medical 2.62, Nolato 1.22, Elekta 2.45.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 1.51–2.35. Peers: Nolato 2.30, Elekta 3.19.
Cash left after investments, divided by the number of shares.
2022–2025: 2.86 SEK–5.20 SEK. Peers: Embla Medical $0.25, Nolato 4.28 SEK, Elekta 4.04 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 71.0%–81.4%.
The dividend explained
A dividend is money paid to shareholders. Vitrolife paid 1.10 SEK per share in the twelve months through November 6, 2026.
On the ex-dividend day, May 6, 2026, Vitrolife traded without the right to the 1.10 SEK dividend. The price went from 108.00 SEK to 108.70 SEK; including the dividend, the day's change was +1.7%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2017: 0.52 SEK2018: 0.74 SEK2019: 0.85 SEK2020: 0.00 SEK2021: 0.80 SEK2022: 0.80 SEK2023: 0.85 SEK2024: 1.00 SEK2025: 1.10 SEK2026 so far: 1.10 SEK
What to watch next, and why
The earnings report shows how Vitrolife's revenue and profit have changed.
- Earnings report
The earnings report shows how Vitrolife's revenue and profit have changed.
Add to calendar
More about Vitrolife
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Bronwyn Brophy O'Connor, CEOBuyabout 270 thousand SEK
- Ermanno Sironi, senior executiveBuyabout 578 thousand SEK
- Pär Svensson Ihrskog, CFOBuyabout 197 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Vitrolife usually moved about 6.3%. On a normal day it moves 0.9%.
+5.01% Why? +10.60% +12.27% −21.52%
10,000 SEK in Vitrolife bought on November 7, 2016 is worth 15,500 SEK today, with dividends reinvested.
What would 10,000 SEK in Vitrolife be worth today? →
What would 10,000 SEK in Vitrolife be worth today?
15,500 SEK
with dividends reinvested, bought on November 7, 2016.
At worst it was worth 8,760 SEK (December 7, 2016).
The five biggest days of the journey
· +28.0% · the whole market fell 0.4% the same day · report day
· +26.9% · the whole market fell 0.6% the same day · report day
· −21.5% · the whole market rose 0.7% the same day · report day
· −17.8% · the whole market fell 0.6% the same day · report day
· −17.5% · the whole market fell 1.5% the same day · report day
Earlier days
+2.21% market −0.32% Vitrolife rose clearly, against a slightly weaker market. Read →
Vitrolife rose clearly, against a slightly weaker market.
No company news from that session explains the move.
Over the last five trading days it rose clearly, more than the market.
The most likely driver is the earlier CEO news: Elin Frostehav, from Getinge, was named new CEO on Monday last week, with Rickard Ericsson as interim CEO from 1 November.
Trading volume was about twice a normal session, so heavy trading accompanied the rise.
+2.26% market +0.83% Vitrolife rose clearly, more than the market. Read →
Vitrolife rose clearly, more than the market.
No company news from that session explains the move.
Over the last five trading days, Vitrolife rose clearly while OMX Stockholm 30 rose slightly.
Earlier news, dated before the session, covered a new CEO, Elin Frostehav, joining from Getinge.
Pareto raised its target price to SEK 105 and kept a hold rating.
−0.78% market +0.48% Vitrolife edged lower, while the market rose slightly. Read →
Vitrolife edged lower, while the market rose slightly.
Over the last five trading days, Vitrolife rose clearly and moved more than the OMX Stockholm 30 did.
Its earnings beat was published in the last session, which is the only news from that day, and it likely helped support the stock over the week.
Last session's move was an ordinary size for Vitrolife, within its usual daily range, and no separate company news explains the slight dip.
+0.96% market −0.29% Vitrolife rose slightly, moving against the market. Read →
Vitrolife rose slightly, moving against the market.
No company news from that session explains it.
The move was an ordinary one for the stock.
Over the last five trading days Vitrolife rose sharply, clearly more than OMX Stockholm 30, a big move for this stock.
Likely drivers include the strong third-quarter report published last week, with higher sales and margins, and a rise in the earnings per share.
+6.16% market +3.01% Vitrolife rose sharply over the week's trading days, clearly outpacing a market that also rose. Read →
Vitrolife rose sharply over the week's trading days, clearly outpacing a market that also rose.
The move was big for the stock, roughly twice a normal five-day stretch.
The main driver was the CEO change announced on Monday 26 October.
Elin Frostehav, head of Getinge's Acute Care Therapies unit, was named chief executive.
+1.33% market +0.41% Vitrolife rose clearly, moving apart from the market. Read →
Vitrolife rose clearly, moving apart from the market.
No company news from that session explains the move.
Over the last five trading days, Vitrolife rose very sharply, well ahead of OMX Stockholm 30.
That is a very big move for Vitrolife, about four times a normal five-day stretch, and similar moves happened about three times in the past year.
The main recent news is the CEO change: Elin Frostehav, a Getinge executive, becomes CEO from 1 May 2027.
+2.66% market +0.96% Vitrolife rose sharply on new CEO appointment. Read →
Vitrolife rose sharply on new CEO appointment.
Vitrolife rose sharply in the last session, while the broader market was roughly flat.
The move is part of a very big five-day rise, about five times a normal stretch for the stock.
The likely driver is the appointment of Elin Frostehav as chief executive, a respected leader from Getinge.
+5.94% market +0.41% Vitrolife rose very sharply. Read →
Vitrolife rose very sharply.
Company news explains the move: the Q3 results and their strong Technologies growth were already out before trading opened, while the call and the sales-beat reports followed the same morning, so the rise likely reflects those results being digested.
Over the last five trading days the stock rose very sharply while OMX Stockholm 30 fell sharply, and the week's move was about four times a normal five-day stretch, a rare size for this stock.
Trading volume was roughly twice a normal session, pointing to strong interest.
The stock sits well below its highest close of the past year and well above its lowest.
+10.85% market −3.67% Vitrolife rose very sharply over the last five trading days, while the OMX Stockholm 30 index fell sharply, so the stock moved against the market. Read →
Vitrolife rose very sharply over the last five trading days, while the OMX Stockholm 30 index fell sharply, so the stock moved against the market.
The likely main driver was its third-quarter report, published yesterday, which showed sales above expectations, with the Technologies product group growing strongly and gross margin, a measure of profit per sale, improving.
Analysts at Pareto raised their target price, the share price they see as fair, to SEK 100 earlier in the week.
The next earnings report is due on Thursday 28 January 2027, so watch for that date.
+5.01% market −2.51% Vitrolife surged on Q3 results. Read →
Vitrolife surged on Q3 results.
Vitrolife rose very sharply in the last session, moving against a falling market.
The move was very big for the stock, about four times a normal day, and trading was well above usual.
The third-quarter report came out that day and showed sales above expectations, led by strong growth in its Technologies group.
Over the last five trading days the shares rose clearly, while the OMX Stockholm 30 fell clearly.
Learn more · Why do stocks go up and down?